nach oben

Erschienen in:

09.05.2023 | Original Article

The outcomes of same-day discharge following holmium laser enucleation of the prostate (HoLEP) surgeries: our experience during the COVID-19 pandemic

verfasst von: Jad Badreddine, Helen Sun, Kimberly Tay, Stephen Rhodes, Daniel Chen, Michael Zell, Irina Jaeger, Amihay Nevo

Erschienen in: World Journal of Urology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

To describe the outcomes of Same-Day Discharge (SDD) following Holmium Laser Enucleation of the Prostate (HoLEP) in patients during the COVID-19 pandemic.

Methods

A retrospective review of HoLEP surgeries at a single institution between January 2021 and March 2022 was performed. Patient demographic and operative data were collected, and postoperative outcomes were evaluated in terms of safety and efficacy and compared in both groups using a t-test and chi-square test. Logistic regression was also performed to identify factors that correlate with the failure of SDD.

Results

A total of 155 patients were identified; 135 patients were successfully discharged on the same day and 20 were admitted (87% SDD rate). Admitted HoLEP patients had a significantly higher median prostate-specific antigen (5.7 vs 3.9 ng/dL, P < 0.001), prostate volume (152.3 vs 100.6 mL, P < 0.001), and enucleated tissue weight (90.3 vs 56.9 g, P = 0.04) compared to the SDD group. The SDD group had a 2.9% (n = 4) readmission rate and a 5.2% (n = 7) Emergency Department (ED) visit rate. There was no significant difference in the rate of postoperative ED visits (P = 0.64), readmissions (P = 0.98), complications, and catheterization time (P = 0.98) between both groups. Preoperative predictors of SDD failure included prostate gland volume > 150 mL (OR = 7.17; CI 2.01–25.67; P < 0.01) and history of antiplatelet/anticoagulation use (OR = 6.59; CI 2.00–21.67; P < 0.01).

Conclusion

Same-day discharge following HoLEP is a safe and effective approach that can be performed in most patients using a liberal discharge criteria and relying on postoperative findings only.

Madersbacher S, Roehrborn CG, Oelke M (2020) The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia. BJU Int 126:317–326. https://doi.org/10.1111/bju.15154CrossRefPubMed

Rocco B, Albo G, Ferreira RC et al (2011) Recent advances in the surgical treatment of benign prostatic hyperplasia. Ther Adv Urol 3:263–272. https://doi.org/10.1177/1756287211426301CrossRefPubMedPubMedCentral

Shvero A, Calio B, Humphreys MR, Das AK (2021) HoLEP: the new gold standard for surgical treatment of benign prostatic hyperplasia. Can J Urol 28:6–10PubMed

Vincent MW, Gilling PJ (2015) HoLEP has come of age. World J Urol 33:487–493. https://doi.org/10.1007/s00345-014-1443-xCrossRefPubMed

B A, HeimanJoshua, LargeTim, et al (2019) Trends and Perioperative Outcomes Across Major Benign Prostatic Hyperplasia Procedures from the ACS-NSQIP 2011–2015. J Endourol. https://doi.org/10.1089/end.2018.0266CrossRef

Shah HN, Mahajan AP, Hegde SS, Bansal MB (2007) Peri-operative complications of holmium laser enucleation of the prostate: experience in the first 280 patients, and a review of literature. BJU Int 100:94–101. https://doi.org/10.1111/j.1464-410X.2007.06867.xCrossRefPubMed

Vavassori I, Valenti S, Naspro R et al (2008) Three-year outcome following holmium laser enucleation of the prostate combined with mechanical morcellation in 330 consecutive patients. Eur Urol 53:599–604. https://doi.org/10.1016/j.eururo.2007.10.059CrossRefPubMed

Comat V, Marquette T, Sutter W et al (2017) Day-case holmium laser enucleation of the prostate: prospective evaluation of 90 consecutive cases. J Endourol 31:1056–1061. https://doi.org/10.1089/end.2017.0196CrossRefPubMed

Gabbay G, Bernhard J-C, Renard O et al (2015) Holmium laser enucleation of the prostate as a day case surgery: prospective evaluation of the first 30 patients. Prog Urol 25:34–39. https://doi.org/10.1016/j.purol.2014.09.048CrossRefPubMed

10.

Agarwal DK, Large T, Tong Y et al (2022) Same day discharge is a successful approach for the majority of patients undergoing holmium laser enucleation of the prostate. Eur Urol Focus 8:228–234. https://doi.org/10.1016/j.euf.2020.12.018CrossRefPubMed

11.

Soltany A, Hamouda M, Ghzawi A et al (2020) A scoping review of the impact of COVID-19 pandemic on surgical practice. Ann Med Surg (Lond) 57:24–36. https://doi.org/10.1016/j.amsu.2020.07.003CrossRefPubMed

12.

Al-Jabir A, Kerwan A, Nicola M et al (2020) Impact of the Coronavirus (COVID-19) pandemic on surgical practice—Part 1. Int J Surg 79:168–179. https://doi.org/10.1016/j.ijsu.2020.05.022CrossRefPubMedPubMedCentral

13.

Stöß C, Steffani M, Kohlhaw K et al (2020) The COVID-19 pandemic: impact on surgical departments of non-university hospitals. BMC Surg 20:313. https://doi.org/10.1186/s12893-020-00970-xCrossRefPubMedPubMedCentral

14.

Lewicki P, Arenas-Gallo C, Basourakos SP, et al (2021) Changes in Urologic Operative Practice at the Beginning of the COVID-19 Pandemic in a Large, National Cohort. Front Oncol 11:684787. https://doi.org/10.3389/fonc.2021.684787

15.

Nazzani S, Preisser F, Mazzone E et al (2018) In-hospital length of stay after major surgical oncological procedures. Eur J Surg Oncol 44:969–974. https://doi.org/10.1016/j.ejso.2018.05.001CrossRefPubMed

16.

Rodríguez Socarrás M, Fernández Del Álamo J, Gómez Rivas J, Gómez Sancha F (2020) En bloc MoLEP (MOSES HoLEP) with early apical dissection and preservation of the sphincter’s mucosa. Surgical technique and technology developments that allow a new paradigm of endoscopic prostate enucleation. Arch Esp Urol 73:689–698PubMed

17.

Larner TRG, Agarwal D, Costello AJ (2003) Day-case holmium laser enucleation of the prostate for gland volumes of < 60 mL: early experience. BJU Int 91:61–64. https://doi.org/10.1046/j.1464-410x.2003.03086.xCrossRefPubMed

18.

Abdul-Muhsin H, Critchlow W, Navaratnam A et al (2020) Feasibility of holmium laser enucleation of the prostate as a 1-day surgery. World J Urol 38:1017–1025. https://doi.org/10.1007/s00345-019-02831-6CrossRefPubMed

19.

Lee S-M, Gordon K, McMillan R et al (2018) Day-case holmium laser enucleation of the prostate: feasibility, safety and predictive factors. Ann R Coll Surg Engl 100:475–479. https://doi.org/10.1308/rcsann.2018.0039CrossRefPubMedPubMedCentral

20.

Lwin AA, Zeng J, Evans P et al (2020) Holmium laser enucleation of the prostate is safe and feasible as a same day surgery. Urology 138:119–124. https://doi.org/10.1016/j.urology.2020.01.014CrossRefPubMed

21.

Assmus MA, Large T, Lee MS et al (2021) Same-day discharge following holmium laser enucleation in patients assessed to have large gland prostates (≥175 cc). J Endourol 35:1386–1392. https://doi.org/10.1089/end.2020.1218CrossRefPubMed

22.

Li P, Wang C, Tang M, et al (2021) Holmium laser enucleation of prostate by using en-bloc and bladder neck preservation technique: technical consideration and influence on functional outcomes. Transl Androl Urol 10:134–142. https://doi.org/10.21037/tau-20-852

23.

Nevo A, Faraj KS, Cheney SM et al (2021) Holmium laser enucleation of the prostate using Moses 2.0 vs non-Moses: a randomised controlled trial. BJU Int 127:553–559. https://doi.org/10.1111/bju.15265CrossRefPubMed

Titel: The outcomes of same-day discharge following holmium laser enucleation of the prostate (HoLEP) surgeries: our experience during the COVID-19 pandemic
verfasst von: Jad Badreddine
Helen Sun
Kimberly Tay
Stephen Rhodes
Daniel Chen
Michael Zell
Irina Jaeger
Amihay Nevo
Publikationsdatum: 09.05.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2023
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-023-04410-2

Neu im Fachgebiet Urologie

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Internistische Arzneimitteltherapie Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

The outcomes of same-day discharge following holmium laser enucleation of the prostate (HoLEP) surgeries: our experience during the COVID-19 pandemic